{"url_path":"/sec/vyne/8-k/2026-07-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-083356-index.html","accession_number":"0001104659-26-083356","cik":"0001566044","ticker":"VYNE","issuer_name":"Yarrow Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-083356-index.html","primary_entity_key":"0001566044","primary_entity_name":"VYNE Therapeutics Inc."},"word_count":78,"has_tables":true,"body_markdown":"**Item 9.01**\n**Financial Statements and Exhibits.**\n\n** **\n\n(d) Exhibits.\n\n \n\n**Exhibit****Number**\n \n**Description**\n\n \n \n \n\n[99.1](tm2620382d1_ex99-1.htm)\n \n[Presentation, dated July\n14, 2026.](tm2620382d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**VYNE THERAPEUTICS INC.**\n\n \n \n\nDate: July 14, 2026\nBy:\n/s/ Mutya Harsch\n\n \n \nMutya Harsch\n\n \n \nChief Legal Officer and General Counsel"}